Hikma Pharmaceuticals (OTCMKTS:HKMPF) has earned a consensus recommendation of “Hold” from the six brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company.
Several research firms have weighed in on HKMPF. Zacks Investment Research raised shares of Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 20th. ValuEngine raised shares of Hikma Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Finally, Jefferies Group downgraded shares of Hikma Pharmaceuticals from a “hold” rating to an “underperform” rating in a research note on Wednesday, January 10th.
HKMPF traded up $2.30 during midday trading on Friday, hitting $18.35. The company had a trading volume of 300 shares, compared to its average volume of 5,200. Hikma Pharmaceuticals has a 52 week low of $12.00 and a 52 week high of $25.35.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.